Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Legal Briefs: AstraZeneca Wins Seroquel Suit, King Settles With DoJ, Sanofi Resolves Gender Discrimination Suit

Executive Summary

AstraZeneca wins first Seroquel product liability trial: A New Jersey state court jury reached a verdict in favor of AstraZeneca, rejecting a plaintiff's claims that the antipsychotic caused his diabetes. The case, Baker v. AstraZeneca, is the first to go to trial. AstraZeneca is facing more than 14,000 Seroquel (quetiapine) lawsuits involving more than 22,000 plaintiffs alleging the company failed to adequately warn of the risk of diabetes. Nine previous cases set for trial were dismissed. The company said that in these cases and in the Baker suit, the facts showed that the plaintiffs either already had diabetes or had so many pre-existing risk factors that they had a significantly increased risk of diabetes before taking Seroquel

You may also be interested in...



Forest Gender Discrimination Suit Cites “Striking” Similarities With Other Firms

Forest is the fourth pharmaceutical company to face a sales rep gender discrimination class action by Sanford Wittels & Heisler; complaint seeks $100 million in damage as well as changes in pay and promotion.

The Era Of Billion Dollar Pharma Settlements

Abbott Laboratories is the third pharmaceutical company to reach a settlement with the Department of Justice in excess of $1 billion. A look at the deals struck since Eli Lilly began the billion dollar club in 2009 shows the activities the government is investigating and the level of liability that companies face.

Sales Reps Prove Compelling Plaintiffs As Novartis Loses Jury Trial Gamble In Gender Discrimination Case; Pay Policy Could Change Industry-wide

The jury verdict in the Novartis gender discrimination class action set a precedent that could impact the entire industry. It is the largest verdict ever awarded in such a case - and damages could extend well beyond that $253.4 million awarded so far if other members of the class come forward

Related Content

Topics

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel